Literature DB >> 9547934

Chronic disulfiram treatment effects on intranasal cocaine administration: initial results.

E F McCance-Katz1, T R Kosten, P Jatlow.   

Abstract

BACKGROUND: Simultaneous abuse of cocaine and alcohol is common. Alcohol decreases negative stimulant effects and potentiates "high." Disulfiram (Antabuse) is being studied in outpatient trials as a cocaine pharmacotherapy with the rationale that inability to modulate cocaine effects with alcohol may decrease cocaine use.
METHODS: We examined the interaction of disulfiram and cocaine in a randomized, double-blind, placebo-controlled study where subjects were chronically treated with disulfiram and then participated in intranasal cocaine administration studies.
RESULTS: Disulfiram 250 mg/day treatment significantly increased plasma cocaine concentrations (p = .013), heart rate (cocaine 1 mg/kg, p = .046), and systolic (cocaine 2 mg/kg p = .003) and diastolic (cocaine 2 mg/kg, p = .022) blood pressure. "High" and "nervous" ratings were nonsignificantly increased.
CONCLUSIONS: The combination of "high" with increased anxiety in the context of inability to lessen negative effects with alcohol may be an effective treatment in selected patients. The significant pharmacokinetic interaction must be considered in the decision regarding use of disulfiram.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9547934     DOI: 10.1016/S0006-3223(97)00506-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  26 in total

Review 1.  Pharmacotherapies for cocaine dependence.

Authors:  G O'Leary; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 2.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 3.  [New developments in the pharmacotherapy of cocaine dependence].

Authors:  G Wiesbeck; K Dürsteler-MacFarland
Journal:  Nervenarzt       Date:  2006-09       Impact factor: 1.214

4.  A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.

Authors:  Helen M Pettinati; Kyle M Kampman; Kevin G Lynch; Hu Xie; Charles Dackis; Amanda R Rabinowitz; Charles P O'Brien
Journal:  Addict Behav       Date:  2007-11-17       Impact factor: 3.913

Review 5.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

6.  Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens.

Authors:  Meriem Gaval-Cruz; Richard B Goertz; Daniel J Puttick; Dawn E Bowles; Rebecca C Meyer; Randy A Hall; Daijin Ko; Carlos A Paladini; David Weinshenker
Journal:  Addict Biol       Date:  2014-08-13       Impact factor: 4.280

7.  Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase.

Authors:  Jason P Schroeder; Debra A Cooper; Jesse R Schank; Megan A Lyle; Meriem Gaval-Cruz; Yvonne E Ogbonmwan; Nikita Pozdeyev; Kimberly G Freeman; P Michael Iuvone; Gaylen L Edwards; Philip V Holmes; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

8.  Cocaine self-administration punished by intravenous histamine in adolescent and adult rats.

Authors:  Nathan A Holtz; Marilyn E Carroll
Journal:  Behav Pharmacol       Date:  2015-06       Impact factor: 2.293

9.  DBH gene as predictor of response in a cocaine vaccine clinical trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Sara C Hamon; David A Nielsen
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.